medi2452
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 23, 2018 (NCT03492385)
Timeline
Indications
Mechanism of action
- TicagrelorINHIBITOR
Ticagrelor inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04286438 | Phase 3 | Mar 1, 2020 | PhaseBio Pharmaceuticals Inc. |
| NCT04122170 | Phase 2 | Oct 14, 2019 | PhaseBio Pharmaceuticals Inc. |
| NCT03928353 | Phase 2 | Apr 17, 2019 | PhaseBio Pharmaceuticals Inc., PPD |
| NCT03492385 | Phase 1 | Mar 23, 2018 | PhaseBio Pharmaceuticals Inc., PPD |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PhaseBio Pharmaceuticals Inc. | For profit | 4 | 4 | 3 | 2018 |
| PPD | For profit | 2 | 0 | 2 | 2018 |
2 organizations
Page 1 / 1